Injectable pre-exposure prophylaxis, commonly called PrEP, is a form of HIV prevention designed for people who do not have HIV but may have a higher chance of acquiring it.
Instead of taking an oral medicine every day, long-acting PrEP uses an injection at scheduled intervals to maintain protective medicine levels in the body. The approach was developed to expand HIV prevention choices and address practical challenges associated with daily medication use.
Injectable PrEP efficacy refers to how well this approach reduces the likelihood of acquiring HIV when compared with another prevention approach or with expected HIV incidence. Clinical evidence for long-acting injectable cabotegravir came from large randomized studies, including HPTN 083 and HPTN 084. These studies compared injectable cabotegravir with daily oral PrEP and found substantially fewer HIV infections among participants receiving the injectable approach.
How Injectable PrEP Works
PrEP medicines work by interfering with HIV replication if the virus enters the body. Long-acting injectable PrEP is designed to maintain medicine levels over an extended period, reducing the need to remember a tablet every day.
The injection schedule depends on the specific medicine and applicable clinical guidance. Regular appointments, HIV testing, and appropriate follow-up remain important because PrEP is intended for people who are HIV-negative when prevention is initiated or continued.
What Clinical Evidence Shows
The two major cabotegravir studies involved different populations. HPTN 083 studied cisgender men and transgender women who have sex with men, while HPTN 084 studied cisgender women in several countries in sub-Saharan Africa. In the primary analyses, injectable cabotegravir reduced HIV incidence by about 66% compared with daily oral TDF-FTC in HPTN 083 and about 88% in HPTN 084.
These percentages describe relative reductions between study groups. They should not be interpreted as meaning that infection is impossible while using injectable PrEP. Breakthrough infections have occurred, including cases associated with infection already present around treatment initiation, delayed injections, or periods after injections were stopped.
Importance
Injectable PrEP efficacy matters because HIV prevention depends not only on biological activity but also on how consistently a prevention method can be used. Daily tablets can be difficult for some people to take regularly because of routines, privacy concerns, travel, changing schedules, or other personal circumstances.
An injectable approach changes the pattern of medication use by replacing frequent tablet-taking with scheduled clinical appointments. This can reduce the need for daily adherence, although it introduces a different requirement: injections must be received according to the recommended schedule.
Who May Consider Injectable PrEP
PrEP is intended for people who are HIV-negative and have a meaningful risk of HIV acquisition. Individual circumstances can vary considerably, so eligibility and the appropriate prevention approach depend on factors such as exposure patterns, current HIV testing results, other health considerations, and local clinical guidance.
Injectable PrEP does not protect against every sexually transmitted infection. It also does not replace other forms of HIV prevention in every situation. A broader prevention approach can include HIV testing, condoms, testing for other sexually transmitted infections, and appropriate clinical follow-up.
Understanding Protection and Adherence
Protection depends on receiving injections at the recommended intervals and maintaining appropriate monitoring. A missed or substantially delayed injection can allow medicine levels to decline, potentially reducing protection.
Another important issue is the long period during which small amounts of some long-acting medicines can remain in the body after injections stop. This period is sometimes called the pharmacologic “tail.” If HIV is acquired while medicine levels are declining, there can be concerns about the development of drug resistance, which is why follow-up and HIV testing are important.
Injectable PrEP Evidence at a Glance
| Evidence area | Key finding |
|---|---|
| HPTN 083 | About 66% lower HIV incidence with injectable cabotegravir than daily oral TDF-FTC in the primary analysis |
| HPTN 084 | About 88% lower HIV incidence with injectable cabotegravir than daily oral TDF-FTC in the primary analysis |
| Dosing pattern | Long-acting injections are administered at scheduled clinical intervals |
| HIV testing | Testing is important before and during continued PrEP use |
| Other infections | Injectable PrEP is specifically intended for HIV prevention and does not prevent all sexually transmitted infections |
| Missed injections | Delays can reduce protection and require appropriate clinical follow-up |
The figures above come from controlled clinical trials and should be interpreted in the context of the populations, procedures, and follow-up periods studied. They do not represent a guarantee of individual protection.
Recent Updates
Research and policy surrounding long-acting HIV prevention have continued to develop during 2024–2026. A major development was the World Health Organization's updated PrEP implementation material, which incorporated oral PrEP, the dapivirine vaginal ring, and long-acting injectable cabotegravir into a broader practical framework for HIV prevention.
Another important development has been the expansion of long-acting PrEP research beyond cabotegravir. In 2025, the World Health Organization added injectable lenacapavir as another long-acting PrEP option, administered twice yearly. This development reflects a broader trend toward prevention methods that require fewer dosing events while maintaining regular HIV testing and clinical monitoring.
Recent guidance has also placed greater attention on HIV testing and drug resistance monitoring. This is particularly relevant for long-acting prevention because a medicine can remain in the body after an injection, while HIV infection may require careful testing to identify accurately during certain stages.
Global adoption remains uneven. WHO data indicate that national PrEP policies differ between countries, and implementation of injectable cabotegravir varies by setting. This means that the availability, eligibility rules, testing procedures, and dosing arrangements can depend on local health guidance.
Tools and Resources
Several resources can help readers understand injectable PrEP efficacy and the evidence behind long-acting HIV prevention.
Clinical Guidelines and Educational Materials
The World Health Organization's PrEP implementation materials explain how oral and long-acting PrEP can be incorporated into HIV prevention programs. They include information relevant to HIV testing, clinical assessment, follow-up, and different PrEP options.
Clinical Trial Evidence
Research records for HPTN 083 and HPTN 084 provide detailed information about study populations, treatment schedules, HIV infection outcomes, and safety findings. These sources are useful when interpreting reported efficacy percentages rather than relying on isolated statistics.
HIV Testing Resources
HIV testing information is another important resource when considering PrEP. Testing helps determine HIV status before starting or continuing prevention and can identify infection that may require a different treatment approach.
Personal Health Records
Keeping a record of injection appointments, HIV testing, laboratory results, and follow-up discussions can help maintain continuity. The exact schedule and monitoring requirements should follow applicable clinical guidance.
FAQs
What is injectable PrEP efficacy?
Injectable PrEP efficacy describes how effectively a long-acting injectable PrEP approach reduces HIV acquisition compared with a comparison group in a clinical study. Results vary according to the medicine, study population, comparison method, and study design.
How effective is injectable PrEP based on clinical evidence?
In the major HPTN 083 and HPTN 084 trials, long-acting injectable cabotegravir produced substantially fewer HIV infections than daily oral TDF-FTC. The primary analyses reported approximately 66% and 88% relative reductions in HIV incidence, respectively.
Does injectable PrEP provide complete protection from HIV?
No prevention method should be described as providing absolute protection. Clinical trials recorded a small number of HIV infections among participants receiving long-acting injectable PrEP, including infections associated with timing, pre-existing infection, or periods after injections were discontinued.
What happens if an injectable PrEP appointment is delayed?
A delayed injection can allow medicine levels to fall and may reduce protection. Appropriate steps depend on how long the injection is delayed, the person's HIV testing status, and the applicable clinical protocol.
Does injectable PrEP prevent other sexually transmitted infections?
Injectable PrEP is designed specifically for HIV prevention. It does not prevent all other sexually transmitted infections, so additional prevention and testing approaches may still be relevant.
Conclusion
Injectable PrEP efficacy is supported by clinical evidence showing substantial reductions in HIV incidence in major randomized trials of long-acting cabotegravir. Protection depends on appropriate dosing schedules, HIV testing, and continued clinical monitoring. Developments through 2024–2026 have expanded the range of long-acting HIV prevention approaches and strengthened guidance around testing and monitoring. Individual circumstances and local clinical guidance determine how injectable PrEP is used.